Albert Labs’ Files U.S. Provisional Patent Application for a Cultivation Process for the Production of Psilocybe mycelia as well as other Fungi Species VANCOUVER, BC, March 30, 2022 /CNW/ – Albert Labs International Corp. (CSE: ABRT) (FSE: VB50) (the “Company”), a research and drug development company using advanced culture technology to create pharmaceutical-quality medicines, based on mycelia of…


Previous articleatai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform
Next articleSilo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study